Novavax to Participate in the Jefferies Global Healthcare Conference

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/01/2023 - 04:02 PM EDT

GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.

Conference Details:
Fireside Chat
Date:		Thursday, June 8, 2023
Time:		9:00 – 9:25 a.m. Eastern Daylight Time (EDT)
Location:		New York, NY
Moderator:		Roger Song, M.D., CFA, Equity Research Analyst – Biotechnology
Novavax participants:		John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research and Development

Conference
Event:		Investor Meetings
Date:		Thursday, June 8, 2023

Recordings
A replay of the recorded fireside session will be available through the Events and Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Ali Chartan
240-709-5563
media@novavax.com